Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.600
-0.030 (-1.84%)
Jun 29, 2026, 2:53 PM EDT - Market open
Entera Bio Employees
As of March 31, 2026, Entera Bio had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees increased by 2 or 10.00% compared to the same quarter last year.
Employees
22
Change
2
Growth
10.00%
Revenue / Employee
n/a
Profits / Employee
-$562,591
Market Cap
78.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 22 | 2 | 10.00% | 20 | 2 |
| Dec 31, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Sep 30, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Jun 30, 2025 | 21 | 2 | 10.53% | 19 | 2 |
| Mar 31, 2025 | 20 | 1 | 5.26% | 18 | 2 |
| Dec 31, 2024 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2024 | 20 | -1 | -4.76% | 18 | 2 |
| Jun 30, 2024 | 19 | -2 | -9.52% | 17 | 2 |
| Mar 31, 2024 | 19 | 1 | 5.56% | 17 | 2 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Sep 30, 2023 | 21 | 2 | 10.53% | 19 | 2 |
| Jun 30, 2023 | 21 | -1 | -4.55% | 19 | 2 |
| Mar 31, 2023 | 18 | -3 | -14.29% | 18 | 0 |
| Dec 31, 2022 | 17 | -3 | -15.00% | 15 | 2 |
| Sep 30, 2022 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Mar 31, 2022 | 21 | 2 | 10.53% | 21 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Heron Therapeutics | 128 |
| MindWalk Holdings | 102 |
| Elicio Therapeutics | 33 |
| Cardiff Oncology | 31 |
| iBio, Inc. | 20 |
| Rallybio | 14 |
| Alterity Therapeutics | 9 |
ENTX News
- 6 days ago - Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewsWire
- 7 days ago - Entera Bio gets FDA feedback on registrational protocol for EB613 - TheFly
- 7 days ago - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - GlobeNewsWire
- 13 days ago - Entera Bio and Opko Health present preclinical data for oral peptides - TheFly
- 13 days ago - Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 - GlobeNewsWire
- 14 days ago - ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) - GlobeNewsWire
- 26 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 26 days ago - Entera Bio Proxy statement: Proxy filing - Filings